Passage BIO Business Summary

Passage Bio, Inc. (PASG) is a clinical-stage genetic medicines company that operates on a pre-revenue business model, currently generating capital through equity financing and interest income rather than product sales. The company specializes in developing one-time, adeno-associated virus (AAV)-delivered gene therapies for rare, monogenic central nervous system (CNS) disorders. Its primary business segment is focused on its lead clinical program, PBFT02, which is undergoing Phase 1/2 trials (upliFT-D) for frontotemporal dementia (FTD) associated with GRN and C9orf72 mutations. As of early 2026, the company has transitioned into a leaner entity by prioritizing its FTD assets and implementing a 1-for-20 reverse stock split in 2025 to maintain its Nasdaq listing. Direct competitors include Alector, Inc., Denali Therapeutics, and Prevail Therapeutics (Eli Lilly); Passage Bio occupies a specialized niche by utilizing a high-productivity, suspension-based manufacturing process to deliver therapeutic transgenes directly to the CNS. The company was co-founded by a prestigious team including Dr. James Wilson, a pioneer in AAV technology and director of the Gene Therapy Program at the University of Pennsylvania, alongside the late Dr. Tachi Yamada and Dr. Stephen Squinto, co-founder of Alexion Pharmaceuticals. The current leadership is headed by President and CEO Will Chou, M.D., an industry veteran who previously led the global commercial launch of the CAR-T therapy Kymriah at Novartis. The executive team also includes CFO Kathleen Borthwick, Chief Scientific Officer Sue Browne, Ph.D., and Chief Business Officer Stuart Henderson. Passage Bio is governed by a board chaired by Dr. Maxine Gowen and is backed by notable institutional investors including BlackRock, Lynx1 Capital Management, and Vestal Point Capital, providing a cash runway that extends into early 2027.